Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 13/20 | 0.78 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.67 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.67 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1674922 | 0.92 | SIRT1 (0.79) | SIRT1SIRT2SIRT3MAPKAPK2ALOX15 | |
| SCHEMBL3484154 | 0.88 | SIRT1 (1.00) | SIRT1SIRT2SIRT3ALOX15LMNA | |
| SCHEMBL11318495 | 0.84 | MAPKAPK2 (0.66) | SIRT1SIRT2SIRT3MAPKAPK2ALOX15 | |
| SCHEMBL16266067 | 0.84 | SIRT1 (0.73) | SIRT1SIRT2SIRT3ALOX15LMNA | |
| SCHEMBL3671656 | 0.83 | SIRT1 (0.85) | SIRT1SIRT2SIRT3LMNAMEN1 | |
| SCHEMBL11682467 | 0.82 | SIRT1 (0.60) | SIRT1SIRT2SIRT3MAPKAPK2ALOX15 | |
| SCHEMBL1875568 | 0.81 | SIRT1 (0.64) | SIRT1SIRT2SIRT3MAPKAPK2ALOX15 | |
| SCHEMBL12990011 | 0.80 | SIRT1 (0.77) | SIRT1SIRT2SIRT3ALOX15LMNA | |
| SCHEMBL1870769 | 0.80 | SIRT1 (1.00) | SIRT1SIRT2SIRT3ALOX15LMNA | |
| SCHEMBL1874310 | 0.80 | SIRT1 (1.00) | SIRT1SIRT2SIRT3ALOX15LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160113903-A1 | SirT INHIBITORS THAT BIND TO NAD | ELIXIR PHARMACEUTICALS, INC. (US) | 2016-04-28 | — | — | US | disclosed |
| US-20140163029-A1 | SirT INHIBITORS THAT BIND TO NAD | ELIXIR PHARMACEUTICALS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20100210692-A1 | METHODS OF TREATMENT USING SIRT MODULATORS AND COMPOSITIONS CONTAINING SIRT1 MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-08-19 | — | — | US | disclosed |
| US-20090306168-A1 | SirT Inhibitors That Bind to NAD | ELIXIR PHARMACEUTICALS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090022694-A1 | SIRT1 INHIBITION | ELIXIR PHARMACEUTICALS, INC. | 2009-01-22 | — | — | US | disclosed |
| US-20080214800-A1 | Deacetylase which uses NAD as a cofactor; treating sirtuin related disorders | ELIXIR PHARMACEUTICALS, INC. | 2008-09-04 | — | — | US | disclosed |
| US-20050256181-A1 | Treating a viral disorder | ELIXIR PHARMACEUTICALS, INC. | 2005-11-17 | — | — | US | disclosed |
| US-20050209300-A1 | Methods of treating a disorder | IPSOL AG (LI) | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160113903-A1 | SirT INHIBITORS THAT BIND TO NAD | SIRT1, SIRT3, SIRT2 | SIRT1 1/4885SIRT2 3/4885SIRT3 2/4885 |
| US-20080214800-A1 | Deacetylase which uses NAD as a cofactor; treating sirtuin related disorders | SIRT3, SIRT1, SIRT2 | SIRT1 2/4885SIRT2 3/4885SIRT3 1/4885 |
| US-20100210692-A1 | METHODS OF TREATMENT USING SIRT MODULATORS AND COMPOSITIONS CONTAINING SIRT1 MODULATORS | SIRT1, SIRT2, SIRT3 | SIRT1 1/4885SIRT2 2/4885SIRT3 3/4885 |
| US-20090022694-A1 | SIRT1 INHIBITION | SIRT1, SIRT2, SIRT3 | SIRT1 1/4885SIRT2 2/4885SIRT3 3/4885 |
| US-20140163029-A1 | SirT INHIBITORS THAT BIND TO NAD | SIRT1, SIRT3, SIRT2 | SIRT1 1/4885SIRT2 3/4885SIRT3 2/4885 |
| US-20050209300-A1 | Methods of treating a disorder | CPT1B, CYP27A1, CLN6 | SIRT1 2717/4885SIRT2 3170/4885SIRT3 2488/4885 |
| US-20090306168-A1 | SirT Inhibitors That Bind to NAD | SIRT1, SIRT3, SIRT2 | SIRT1 1/4885SIRT2 3/4885SIRT3 2/4885 |
| US-20050256181-A1 | Treating a viral disorder | HAVCR2, EIF2AK2, RPL35 | SIRT1 1460/4885SIRT2 2707/4885SIRT3 1934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.